Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy

Hyun Yi Kim, Sehee Choi, Ji Hye Yoon, Hwan Jung Lim, Hyuk Lee, Jiwon Choi, Eun Ji Ro, Jung Nyoung Heo, Weontae Lee, Kyoung Tai No, Kang Yell Choi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Bone anabolic agents promoting bone formation and rebuilding damaged bones would ideally overcome the limitations of anti-resorptive therapy, the current standard prescription for osteoporosis. However, the currently prescribed parathyroid hormone (PTH)-based anabolic drugs present limitations and adverse effects including osteosarcoma during long-term use. Also, the antibody-based anabolic drugs that are currently being developed present the potential limits in clinical application typical of macromolecule drugs. We previously identified that CXXC5 is a negative feedback regulator of the Wnt/β-catenin pathway via its interaction with Dishevelled (Dvl) and suggested the Dvl-CXXC5 interaction as a potential target for anabolic therapy of osteoporosis. Here, we screened small-molecule inhibitors of the Dvl-CXXC5 interaction via a newly established invitro assay system. The screened compounds were found to activate the Wnt/β-catenin pathway and enhance osteoblast differentiation in primary osteoblasts. The bone anabolic effects of the compounds were shown using exvivo-cultured calvaria. Nuclear magnetic resonance (NMR) titration analysis confirmed interaction between Dvl PDZ domain and KY-02061, a representative of the screened compounds. Oral administration of KY-02327, one of 55 newly synthesized KY-02061 analogs, successfully rescued bone loss in the ovariectomized (OVX) mouse model. In conclusion, small-molecule inhibitors of the Dvl-CXXC5 interaction that block negative feedback regulation of Wnt/β-catenin signaling are potential candidates for the development of bone anabolic anti-osteoporosis drugs.

Original languageEnglish
Pages (from-to)375-387
Number of pages13
JournalEMBO Molecular Medicine
Volume8
Issue number4
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Drug Interactions
Catenins
Osteoporosis
Anabolic Agents
Bone and Bones
Wnt Signaling Pathway
Osteoblasts
Pharmaceutical Preparations
PDZ Domains
Bone Development
Osteosarcoma
Therapeutics
Parathyroid Hormone
Osteogenesis
Skull
Prescriptions
Oral Administration
Magnetic Resonance Spectroscopy
Antibodies

All Science Journal Classification (ASJC) codes

  • Molecular Medicine

Cite this

Kim, Hyun Yi ; Choi, Sehee ; Yoon, Ji Hye ; Lim, Hwan Jung ; Lee, Hyuk ; Choi, Jiwon ; Ro, Eun Ji ; Heo, Jung Nyoung ; Lee, Weontae ; No, Kyoung Tai ; Choi, Kang Yell. / Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. In: EMBO Molecular Medicine. 2016 ; Vol. 8, No. 4. pp. 375-387.
@article{0823853e82704fd9b76c9bca12e14262,
title = "Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy",
abstract = "Bone anabolic agents promoting bone formation and rebuilding damaged bones would ideally overcome the limitations of anti-resorptive therapy, the current standard prescription for osteoporosis. However, the currently prescribed parathyroid hormone (PTH)-based anabolic drugs present limitations and adverse effects including osteosarcoma during long-term use. Also, the antibody-based anabolic drugs that are currently being developed present the potential limits in clinical application typical of macromolecule drugs. We previously identified that CXXC5 is a negative feedback regulator of the Wnt/β-catenin pathway via its interaction with Dishevelled (Dvl) and suggested the Dvl-CXXC5 interaction as a potential target for anabolic therapy of osteoporosis. Here, we screened small-molecule inhibitors of the Dvl-CXXC5 interaction via a newly established invitro assay system. The screened compounds were found to activate the Wnt/β-catenin pathway and enhance osteoblast differentiation in primary osteoblasts. The bone anabolic effects of the compounds were shown using exvivo-cultured calvaria. Nuclear magnetic resonance (NMR) titration analysis confirmed interaction between Dvl PDZ domain and KY-02061, a representative of the screened compounds. Oral administration of KY-02327, one of 55 newly synthesized KY-02061 analogs, successfully rescued bone loss in the ovariectomized (OVX) mouse model. In conclusion, small-molecule inhibitors of the Dvl-CXXC5 interaction that block negative feedback regulation of Wnt/β-catenin signaling are potential candidates for the development of bone anabolic anti-osteoporosis drugs.",
author = "Kim, {Hyun Yi} and Sehee Choi and Yoon, {Ji Hye} and Lim, {Hwan Jung} and Hyuk Lee and Jiwon Choi and Ro, {Eun Ji} and Heo, {Jung Nyoung} and Weontae Lee and No, {Kyoung Tai} and Choi, {Kang Yell}",
year = "2016",
month = "4",
day = "1",
doi = "10.15252/emmm.201505714",
language = "English",
volume = "8",
pages = "375--387",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "4",

}

Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. / Kim, Hyun Yi; Choi, Sehee; Yoon, Ji Hye; Lim, Hwan Jung; Lee, Hyuk; Choi, Jiwon; Ro, Eun Ji; Heo, Jung Nyoung; Lee, Weontae; No, Kyoung Tai; Choi, Kang Yell.

In: EMBO Molecular Medicine, Vol. 8, No. 4, 01.04.2016, p. 375-387.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy

AU - Kim, Hyun Yi

AU - Choi, Sehee

AU - Yoon, Ji Hye

AU - Lim, Hwan Jung

AU - Lee, Hyuk

AU - Choi, Jiwon

AU - Ro, Eun Ji

AU - Heo, Jung Nyoung

AU - Lee, Weontae

AU - No, Kyoung Tai

AU - Choi, Kang Yell

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Bone anabolic agents promoting bone formation and rebuilding damaged bones would ideally overcome the limitations of anti-resorptive therapy, the current standard prescription for osteoporosis. However, the currently prescribed parathyroid hormone (PTH)-based anabolic drugs present limitations and adverse effects including osteosarcoma during long-term use. Also, the antibody-based anabolic drugs that are currently being developed present the potential limits in clinical application typical of macromolecule drugs. We previously identified that CXXC5 is a negative feedback regulator of the Wnt/β-catenin pathway via its interaction with Dishevelled (Dvl) and suggested the Dvl-CXXC5 interaction as a potential target for anabolic therapy of osteoporosis. Here, we screened small-molecule inhibitors of the Dvl-CXXC5 interaction via a newly established invitro assay system. The screened compounds were found to activate the Wnt/β-catenin pathway and enhance osteoblast differentiation in primary osteoblasts. The bone anabolic effects of the compounds were shown using exvivo-cultured calvaria. Nuclear magnetic resonance (NMR) titration analysis confirmed interaction between Dvl PDZ domain and KY-02061, a representative of the screened compounds. Oral administration of KY-02327, one of 55 newly synthesized KY-02061 analogs, successfully rescued bone loss in the ovariectomized (OVX) mouse model. In conclusion, small-molecule inhibitors of the Dvl-CXXC5 interaction that block negative feedback regulation of Wnt/β-catenin signaling are potential candidates for the development of bone anabolic anti-osteoporosis drugs.

AB - Bone anabolic agents promoting bone formation and rebuilding damaged bones would ideally overcome the limitations of anti-resorptive therapy, the current standard prescription for osteoporosis. However, the currently prescribed parathyroid hormone (PTH)-based anabolic drugs present limitations and adverse effects including osteosarcoma during long-term use. Also, the antibody-based anabolic drugs that are currently being developed present the potential limits in clinical application typical of macromolecule drugs. We previously identified that CXXC5 is a negative feedback regulator of the Wnt/β-catenin pathway via its interaction with Dishevelled (Dvl) and suggested the Dvl-CXXC5 interaction as a potential target for anabolic therapy of osteoporosis. Here, we screened small-molecule inhibitors of the Dvl-CXXC5 interaction via a newly established invitro assay system. The screened compounds were found to activate the Wnt/β-catenin pathway and enhance osteoblast differentiation in primary osteoblasts. The bone anabolic effects of the compounds were shown using exvivo-cultured calvaria. Nuclear magnetic resonance (NMR) titration analysis confirmed interaction between Dvl PDZ domain and KY-02061, a representative of the screened compounds. Oral administration of KY-02327, one of 55 newly synthesized KY-02061 analogs, successfully rescued bone loss in the ovariectomized (OVX) mouse model. In conclusion, small-molecule inhibitors of the Dvl-CXXC5 interaction that block negative feedback regulation of Wnt/β-catenin signaling are potential candidates for the development of bone anabolic anti-osteoporosis drugs.

UR - http://www.scopus.com/inward/record.url?scp=84960157484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960157484&partnerID=8YFLogxK

U2 - 10.15252/emmm.201505714

DO - 10.15252/emmm.201505714

M3 - Article

C2 - 26941261

AN - SCOPUS:84960157484

VL - 8

SP - 375

EP - 387

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 4

ER -